AIM: The aim was to evaluate the in vitro activity of fosfomycin against common uropathogens in a fosfomycin-naive population in India. METHODS: The authors prospectively collected and tested all consecutive isolates of Escherichia coli and Enterococcus spp. from urine samples between December 2009 and April 2010. RESULTS: A total of 3141 isolates were included in the study, 2416 E. coli and 725 Enterococcus spp. Fosfomycin was the most active antibiotic against both pathogens with an overall susceptibility of 83 and 99% for E. coli and Enterococcus spp, respectively. Among E. coli, 47.6% of the isolates were extended-spectrum β-lactamase producing, of which 81% were susceptible to fosfomycin, while 51.5% were multidrug resistant, with 75.7% of this portion being susceptible to fosfomycin. CONCLUSION: Fosfomycin exhibits good in vitro activity against both the uropathogens tested. Therefore, it might be considered as a treatment option for urinary tract infections in India; however, clinical trials should first reinforce the in vitro findings.
AIM: The aim was to evaluate the in vitro activity of fosfomycin against common uropathogens in a fosfomycin-naive population in India. METHODS: The authors prospectively collected and tested all consecutive isolates of Escherichia coli and Enterococcus spp. from urine samples between December 2009 and April 2010. RESULTS: A total of 3141 isolates were included in the study, 2416 E. coli and 725 Enterococcus spp. Fosfomycin was the most active antibiotic against both pathogens with an overall susceptibility of 83 and 99% for E. coli and Enterococcus spp, respectively. Among E. coli, 47.6% of the isolates were extended-spectrum β-lactamase producing, of which 81% were susceptible to fosfomycin, while 51.5% were multidrug resistant, with 75.7% of this portion being susceptible to fosfomycin. CONCLUSION:Fosfomycin exhibits good in vitro activity against both the uropathogens tested. Therefore, it might be considered as a treatment option for urinary tract infections in India; however, clinical trials should first reinforce the in vitro findings.
Authors: María Ruiz-Ruigómez; Mario Fernández-Ruiz; José Tiago Silva; Elisa Vidal; Julia Origüen; Antonia Calvo-Cano; Enrique Luna-Huerta; Esperanza Merino; Domingo Hernández; Cristina Jironda-Gallegos; Rosa Escudero-Sánchez; Francesca Gioia; Antonio Moreno; Cristina Roca; Elisa Cordero; Darío Janeiro; Beatriz Sánchez-Sobrino; María Milagro Montero; Dolores Redondo; Francisco Javier Candel; Isabel Pérez-Flores; Carlos Armiñanzas; Claudia González-Rico; María Carmen Fariñas; Emilio Rodrigo; Belén Loeches; María O López-Oliva; Miguel Montejo; Ricardo Lauzurica; Juan Pablo Horcajada; Julio Pascual; Amado Andrés; José María Aguado; Francisco López-Medrano Journal: Antimicrob Agents Chemother Date: 2021-02-08 Impact factor: 5.191
Authors: Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132
Authors: Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland Journal: Drugs Date: 2017-06 Impact factor: 9.546
Authors: Yazeed A Al Sheikh; Mohammed Ali M Marie; James John; Lakshmana Gowda Krishnappa; Khaled Homoud M Dabwab Journal: Libyan J Med Date: 2014-07-07 Impact factor: 1.743